Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
No risks detected for ALXN from our risk checks.
Outstanding track record and undervalued.
Share Price & News
How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALXN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ALXN underperformed the Austrian Biotechs industry which returned 29.2% over the past year.
Return vs Market: ALXN exceeded the Austrian Market which returned -21.4% over the past year.
Price Volatility Vs. Market
How volatile is Alexion Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Alexion Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALXN (€99.78) is trading below our estimate of fair value (€152.32)
Significantly Below Fair Value: ALXN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALXN is good value based on its PE Ratio (10.5x) compared to the Biotechs industry average (40x).
PE vs Market: ALXN is good value based on its PE Ratio (10.5x) compared to the Austrian market (11x).
Price to Earnings Growth Ratio
PEG Ratio: ALXN is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: ALXN is good value based on its PB Ratio (2.1x) compared to the XE Biotechs industry average (4.4x).
How is Alexion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALXN's forecast earnings growth (8.4% per year) is above the savings rate (0.5%).
Earnings vs Market: ALXN's earnings (8.4% per year) are forecast to grow slower than the Austrian market (21.6% per year).
High Growth Earnings: ALXN's earnings are forecast to grow, but not significantly.
Revenue vs Market: ALXN's revenue (7.1% per year) is forecast to grow faster than the Austrian market (3.4% per year).
High Growth Revenue: ALXN's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALXN's Return on Equity is forecast to be low in 3 years time (15.9%).
How has Alexion Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALXN has high quality earnings.
Growing Profit Margin: ALXN's current net profit margins (44.8%) are higher than last year (9.8%).
Past Earnings Growth Analysis
Earnings Trend: ALXN's earnings have grown significantly by 42.1% per year over the past 5 years.
Accelerating Growth: ALXN's earnings growth over the past year (456.7%) exceeds its 5-year average (42.1% per year).
Earnings vs Industry: ALXN earnings growth over the past year (456.7%) exceeded the Biotechs industry 16.5%.
Return on Equity
High ROE: ALXN's Return on Equity (20.2%) is considered high.
How is Alexion Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ALXN's short term assets ($4.9B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: ALXN's short term assets ($4.9B) do not cover its long term liabilities ($5.3B).
Debt to Equity History and Analysis
Debt Level: ALXN's debt to equity ratio (21.8%) is considered satisfactory.
Reducing Debt: ALXN's debt to equity ratio has increased from 3.3% to 21.8% over the past 5 years.
Debt Coverage: ALXN's debt is well covered by operating cash flow (86%).
Interest Coverage: ALXN's interest payments on its debt are well covered by EBIT (91.9x coverage).
What is Alexion Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALXN's dividend in 3 years as they are not forecast to pay a notable one for the Austrian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ludwig Hantson (57yo)
Dr. Ludwig N. Hantson, Ph.D., has been Chief Executive Officer at Alexion Pharmaceuticals, Inc. since March 27, 2017. Dr. Hantson has been the President of Synovis Life Technologies Inc. since February 14, ...
CEO Compensation Analysis
Compensation vs Market: Ludwig's total compensation ($USD18.95M) is above average for companies of similar size in the Austrian market ($USD3.99M).
Compensation vs Earnings: Ludwig's compensation has been consistent with company performance over the past year.
|CEO & Director||3.33yrs||US$18.95m||0.042% $9.3m|
|Executive VP & CFO||0.75yr||US$4.88m||0.0047% $1.0m|
|Executive VP and Chief Commercial & Global Operations Officer||0.75yr||US$5.55m||0.0099% $2.2m|
|Executive VP & Chief Human Experience Officer||3.08yrs||US$5.14m||0.0066% $1.5m|
|Executive VP and Head of Research & Development||3.08yrs||US$5.63m||0.0072% $1.6m|
|Executive VP & Senior Advisor||0.75yr||US$5.87m||0.021% $4.7m|
|Chief Accounting Officer & Senior VP||no data||no data||0.0064% $1.4m|
|Head of Investor Relations||no data||no data||no data|
|Executive VP & Chief Compliance Officer||3.08yrs||no data||0.0020% $450.0k|
|Executive VP||2.42yrs||no data||0.0020% $439.0k|
Experienced Management: ALXN's management team is considered experienced (2.8 years average tenure).
|CEO & Director||3.33yrs||US$18.95m||0.042% $9.3m|
|Independent Director||5.08yrs||US$470.05k||0.060% $13.2m|
|Independent Director||2.83yrs||US$445.05k||0.0019% $414.7k|
|Independent Director||2.5yrs||US$445.07k||0.0022% $480.9k|
|Independent Chairman of the Board||3.17yrs||US$595.05k||0.0038% $842.6k|
|Independent Director||2.42yrs||US$470.01k||0.0021% $461.0k|
|Independent Director||10.42yrs||US$445.05k||0.0088% $1.9m|
|Independent Director||6.25yrs||US$470.05k||0.0029% $650.7k|
|Independent Director||2.67yrs||US$445.05k||0.0019% $414.7k|
Experienced Board: ALXN's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alexion Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Alexion Pharmaceuticals, Inc.
- Ticker: ALXN
- Exchange: WBAG
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$24.799b
- Listing Market Cap: US$22.059b
- Shares outstanding: 220.83m
- Website: https://www.alexion.com
Number of Employees
- Alexion Pharmaceuticals, Inc.
- 121 Seaport Boulevard
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALXN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 1996|
|AXP||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Feb 1996|
|AXP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 1996|
|ALXN||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Feb 1996|
|0QZM||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 1996|
|ALXN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Feb 1996|
|ALXN||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Feb 1996|
|AXP-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Feb 1996|
|A1LX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 2 COM||BR||BRL||Dec 2019|
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/05 21:15|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.